Rhumbline Advisers Sells 8,857 Shares of Roche Holding AG (OTCMKTS:RHHBY)

Rhumbline Advisers reduced its stake in shares of Roche Holding AG (OTCMKTS:RHHBY - Free Report) by 8.1% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 99,878 shares of the company's stock after selling 8,857 shares during the quarter. Rhumbline Advisers' holdings in Roche were worth $3,484,000 at the end of the most recent reporting period.

Other hedge funds have also added to or reduced their stakes in the company. Bard Financial Services Inc. increased its position in Roche by 37.7% during the 4th quarter. Bard Financial Services Inc. now owns 110,850 shares of the company's stock valued at $3,866,000 after purchasing an additional 30,350 shares during the period. Diversified Trust Co grew its position in shares of Roche by 1.2% in the 4th quarter. Diversified Trust Co now owns 60,453 shares of the company's stock worth $2,130,000 after buying an additional 711 shares during the period. Hantz Financial Services Inc. grew its position in shares of Roche by 0.9% in the 4th quarter. Hantz Financial Services Inc. now owns 33,708 shares of the company's stock worth $1,176,000 after buying an additional 305 shares during the period. Brooklyn Investment Group grew its position in shares of Roche by 36.6% in the 4th quarter. Brooklyn Investment Group now owns 1,354 shares of the company's stock worth $48,000 after buying an additional 363 shares during the period. Finally, Canopy Partners LLC grew its position in shares of Roche by 4.6% in the 3rd quarter. Canopy Partners LLC now owns 7,772 shares of the company's stock worth $310,000 after buying an additional 344 shares during the period.

Roche Price Performance

Roche stock traded up $0.09 during mid-day trading on Monday, reaching $41.83. The stock had a trading volume of 1,660,494 shares, compared to its average volume of 2,896,557. The company has a 50-day moving average price of $38.38 and a two-hundred day moving average price of $38.41. Roche Holding AG has a one year low of $29.20 and a one year high of $42.43. The company has a debt-to-equity ratio of 0.86, a quick ratio of 0.97 and a current ratio of 1.26.

Analyst Ratings Changes

RHHBY has been the topic of a number of recent research reports. Sanford C. Bernstein raised shares of Roche to a "strong-buy" rating in a research report on Thursday, January 30th. Morgan Stanley initiated coverage on shares of Roche in a research report on Wednesday, February 12th. They issued an "equal weight" rating on the stock. Finally, UBS Group upgraded shares of Roche from a "hold" rating to a "strong-buy" rating in a research note on Thursday, February 13th. Two analysts have rated the stock with a sell rating, two have issued a hold rating, one has issued a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, the stock currently has an average rating of "Hold".

Roche Company Profile

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation.